CClinicalTrials.gg
CompletedNCT02970357PROGETEUpdated Nov 20, 2025

Evaluation of the Impact of a Therapeutic Education Program for Children With Type 1 Diabetes

An interventional study of DIAPASON Questionnaire and WHO-5 in Diabetes Mellitus, Type I, Program Evaluation and Therapeutic Education, sponsored by Groupe Hospitalier de la Region de Mulhouse et Sud Alsace. Completed at 1 site in France. Open to participants aged 10 Years to 20 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Groupe Hospitalier de la Region de Mulhouse et Sud Alsace · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2016, registered Oct 2016).
Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
10 Years to 20 Years
Sex
All
01

Study summary

The needs of children and teens with type 1 diabetes are very specific and different from the adults with type 1 diabetes. Many organizations such as the World Health Organization or the International Society for Pediatric and Adolescent Diabetes, recommend a patient therapeutic education when it comes to children with type 1 diabetes.

This study aims to evaluate the impact of a therapeutic education program on theoretical knowledge of the disease and also on quality of life, on biological and clinical indicators.

Read the detailed description

Structuring a therapeutic education program for patients with a chronic disease was the initiative of the French High Health Authority in June 2007.

The Prevention and Care of Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse is a partner of the Mulhouse Hospital. Besides the usual care given at the hospital of Mulhouse for patients with a type 1 diabetes, both organizations also provide therapeutic education to these patients.

Each therapeutic education program is organized according to the patient's age. They can also be organized in a group or individually.

The aim of the therapeutic education is to help the young patients to cope with diabetes in their daily activities. Therapeutic education is known to bring good results for patients with diabetes, but there is no studies in France for children and teens with a type 1 diabetes.

02

Conditions studied

  • Diabetes Mellitus, Type I
  • Program Evaluation
  • Therapeutic Education
  • Children

Keywords

  • Evaluation
  • Therapeutic education
  • Type 1 Diabetes
  • Children
03

In context

Diabetes Mellitus, Type 1

3,522 studies on the registry are indexed under Diabetes Mellitus, Type 1; 577 are open to participants now.

This study's enrollment of 68 is above the median of 40 across 2,649 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Groupe Hospitalier de la Region de Mulhouse et Sud Alsace is the lead sponsor of 27 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Enrollment between January 15 to March 15, 2016
  • Insulin-dependent type 1 Diabetes
  • Treatment received at the Hospital of Mulhouse, France

Exclusion criteria

Exclusion Criteria:

  • Opposition to study participation
  • Behavioral issues
  • Uncontrolled psychological issue
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Other
    Enrolled patient

    Every patient of the Mulhouse Hospital with a type 1 diabetes who joins the study will be followed for 10 months. They will fill in the DIAPASON questionnaire and the quality of life WHO-5 questionnaire on the day of enrollment and 10 months after enrollment, at the end of the study. Young patients followed for a type 1 diabetes at the Mulhouse Hospital usually come every two months to see the pediatric endocrinologist, so the data collected for a regular visit will also be collected for the study every two months between the enrollment and the end of study participation.

    Other: DIAPASON Questionnaire · Behavioral: WHO-5

Interventions

  • OtherDIAPASON Questionnaire

    50 item questionnaire of the French Youth Diabetes Association to evaluate one's theoretical knowledge about the diabetes disease. 6 main themes are evaluated : * what is diabetes * Monitoring * Hypoglycemia and Hyperglycemia * Nutrition * Insuline

  • BehavioralWHO-5

    5 item questionnaire of the World Health Organization about quality of life

    Also known as: Quality of Life Questionnaire

06

What researchers measure

Primary outcomes

  1. The DIAPASON questionnaire

    50 item questionnaire that evaluates the patient's theoretical knowledge of the type 1 diabetes disease. Questionnaire submitted to patients and a parent.

    Time frame: The outcome will be the change of the answers to the questionnaire from enrollment to the end of the study, ten months later.

Secondary outcomes

  1. Evolution of glycated hemoglobin

    Time frame: Throughout the study : on the enrollment day, 2 months after enrollment, 4 months after enrollment, 6 months after enrollment, 8 months after enrollment and 10 months after enrollment which is the end of the study participation

  2. Occurrence of severe hypoglycemic events

    Time frame: Throughout the study : on the enrollment day, 2 months after enrollment, 4 months after enrollment, 6 months after enrollment, 8 months after enrollment and 10 months after enrollment which is the end of the study participation

  3. Occurrence of ketoacidosis events

    Time frame: Throughout the study : on the enrollment day, 2 months after enrollment, 4 months after enrollment, 6 months after enrollment, 8 months after enrollment and 10 months after enrollment which is the end of the study participation

  4. Need for care indicators

    Visits to the emergency room of a hospital, consultation with general practitioner

    Time frame: Throughout the study : on the enrollment day, 2 months after enrollment, 4 months after enrollment, 6 months after enrollment, 8 months after enrollment and 10 months after enrollment which is the end of the study participation

  5. Behavioral indicators

    Evaluation of diabètes self-management, participation to therapeutic programs

    Time frame: Throughout the study : on the enrollment day, 2 months after enrollment, 4 months after enrollment, 6 months after enrollment, 8 months after enrollment and 10 months after enrollment which is the end of the study participation

  6. Psychological indicators

    quality of life questionnaire for patient and parent

    Time frame: On day 1, at enrollment, and 10months later, at the end of the study participation

07

Study locations

1 site
  • GHRMSA
    Mulhouse, France
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02970357
Lead sponsor
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Responsible party
Sponsor
First posted
Nov 22, 2016
Start date
Jan 26, 2016
Primary completion
Mar 20, 2017
Completion
Mar 20, 2017
Last update
Nov 20, 2025

Study contacts

Fatiha GUEMAZI-KHEFFI, MD
principal investigator · Groupe Hospitalier de la Région de Mulhouse et Sud Alsace

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion